Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(UCLA Health), Beverly Moy(Global Cancer Institute), Laura M. Spring(Massachusetts General Hospital), Seth A. Wander(Harvard University), Andrzej Niemierko(Harvard University), Neelima Vidula(Harvard University), Leif W. Ellisen(Harvard University), Sara M. Tolaney(Harvard University), Jennifer Goff(Harvard University), Elizabeth Abraham(Temple College), Dejan Juric(Massachusetts General Hospital), Heather A. Parsons(Harvard University), Adrienne G. Waks(Harvard University), Steven J. Isakoff(Harvard University), Amanda Valenti(Harvard University), Mary McNeice(Harvard University)
Cited by 6
Related Papers
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k